Unibest
← Back to patent-cliff list

Foslinanib

Tier C — Watch / trade

Foslinanib

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:Not applicable

Indications (approved):Hepatocellular carcinoma, 肺神经内分泌癌, Neuroendocrine carcinoma, Neuroendocrine tumour, 胃肠胰神经内分泌肿瘤, 胰岛细胞腺瘤, Solid tumour, 转移性上皮癌

Regional status

US
Discontinued
2018-07-12
EU
-
China
Phase II
2026-03-31
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 0Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OptimisedRoute 1Steps 7 · Total yield 2.00%
Foslinanib-00198300-41-5Foslinanib-0021711-07-5Foslinanib-0031256037-07-6Foslinanib-0041256037-25-8Foslinanib-005—Foslinanib-006990-91-0Foslinanib-0071256037-56-5Foslinanib-0081256037-58-7Foslinanib-0091256037-60-1Foslinanib1256037-62-3API · Foslinanib
CodeCAS No.Intermediate
Foslinanib-00198300-41-51-(6-amino-2,3-dimethoxyphenyl)ethan-1-one
Foslinanib-0021711-07-53-fluorobenzoyl chloride
Foslinanib-0031256037-07-6N-(2-acetyl-3,4-dimethoxyphenyl)-3-fluorobenzamide
Foslinanib-0041256037-25-82-(3-fluorophenyl)-5,6-dimethoxyquinolin-4(1H)-one
Foslinanib-005-2-(3-fluorophenyl)-5-hydroxy-6-methoxyquinolin-4(1H)-one
Foslinanib-006990-91-0tetrabenzyl diphosphate
Foslinanib-0071256037-56-5tetrabenzyl (2-(3-fluorophenyl)-6-methoxyquinoline-4,5-diyl) bis(phosphate)
Foslinanib-0081256037-58-7dibenzyl (2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl) phosphate
Foslinanib-0091256037-60-12-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl dihydrogen phosphate
Foslinanib1256037-62-34(1H)-Quinolinone, 2-(3-fluorophenyl)-6-methoxy-5-(phosphonooxy)-, sodium salt (1:2)

Frequently asked questions

What are the approved indications of Foslinanib?

Approved indications include: Hepatocellular carcinoma, 肺神经内分泌癌, Neuroendocrine carcinoma, Neuroendocrine tumour, 胃肠胰神经内分泌肿瘤, 胰岛细胞腺瘤, Solid tumour, 转移性上皮癌.

When does the Foslinanib patent expire?

No public expiry year is available for Foslinanib yet; this page updates once verified.

How many synthesis routes are recorded for Foslinanib?

1 synthesis routes are recorded; the shortest is 7 steps with 2.00% total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Foslinanib intermediates?

All intermediates in Foslinanib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Foslinanib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-08